Kater, A. P., Harrup, R. A., Kipps, T. J., Eichhorst, B., Owen, C., Assouline, S. E., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Langerak, A. W., Chyla, B., Popovic, R., Jiang, Y., Millen, R., Lefebure, M., … Seymour, J. F. (2025). The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL. Blood Journal. https://doi.org/10.1182/blood.2024025525

Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer. (2024). Journal of the College of Physicians and Surgeons Pakistan, 34(06), 682–687. https://doi.org/10.29271/jcpsp.2024.06.682

Topping, R. P., Quill, T. A., Lamanna, N., & Sharman, J. P. (2023). Determining Clinical Practice Gaps for HCPs in Treating CLL Using CME-Based Surveys. Blood, 142(Supplement 1), 3716–3716. https://doi.org/10.1182/blood-2023-190329

Kim, S., Armand, J., Safonov, A., Zhang, M., Soni, R. K., Schwartz, G., McGuinness, J. E., Hibshoosh, H., Razavi, P., Kim, M., Chandarlapaty, S., & Yang, H. W. (2023). Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer. Cell Reports, 42(11), 113198. https://doi.org/10.1016/j.celrep.2023.113198

Kater, A. P., Harrup, R., Kipps, T. J., Eichhorst, B., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., Serna, J. d. l., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Thadani‐Mulero, M., Lefebure, M., Jiang, Y., Millen, R., Boyer, M., & Seymour, J. F. (2023). MURANO: Final 7 year follow up and retreatment analysis in venetoclax‐rituximab (VenR)‐treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematological Oncology, 41(S2), 239–242. Portico. https://doi.org/10.1002/hon.3163_156

Graff, S. L., Bansal, R., Adeyelu, T., Elliott, A., Bustos, M., Rodriguez, E., Accordino, M., Meisel, J., Gatti-Mays, M., Hsu, E., Lathrop, K. I., Kaklamani, V., Oberley, M., Sledge, G., & Sammons, S. (2023). 215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer. ESMO Open, 8(1), 101404. https://doi.org/10.1016/j.esmoop.2023.101404

Sivakumar, S., Jin, D. X., Rathod, R., Ross, J., Cantley, L. C., Scaltriti, M., Chen, J. W., Hutchinson, K. E., Wilson, T. R., Sokol, E. S., & Vasan, N. (2023). Genetic Heterogeneity and Tissue-specific Patterns of Tumors with MultiplePIK3CAMutations. Clinical Cancer Research, 29(6), 1125–1136. https://doi.org/10.1158/1078-0432.ccr-22-2270

Peng, K., Zhang, F., Wang, Y., Sahgal, P., Li, T., Zhou, J., Liang, X., Zhang, Y., Sethi, N., Liu, T., Zhang, H., & Bass, A. J. (2022). Development of Combination Strategies for Focal Adhesion Kinase Inhibition in Diffuse Gastric Cancer. Clinical Cancer Research, 29(1), 197–208. https://doi.org/10.1158/1078-0432.ccr-22-1609

Kim, S., Leong, A., Kim, M., & Yang, H. W. (2022). CDK4/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1/S transition. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-20769-5

Shah, N. N., Wang, M. L., Brown, J. R., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Gastinne, T., Ghia, P., Lamanna, N., Hoffmann, M., Patel, M. R., Flinn, I. W., Gerson, J. N., Ma, S., Coombs, C. C., … Mato, A. R. (2022). Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 4127–4132. https://doi.org/10.1182/blood-2022-159035

Wenham, R., Ghamande, S., Makker, V., Hou, J., Duska, L., Matei, D., Bhave, M., Scott, R., Hawk, N., Song, T., & Armstrong, D. K. (2022). 2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types. Ovarian Cancer, A312.3-A313. https://doi.org/10.1136/ijgc-2022-esgo.667

Vikas, P., Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022). Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice, 18(9), 649–651. https://doi.org/10.1200/op.22.00284

O’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S., Hamilton, E., Loirat, D., Traina, T., Leon-Ferre, R., Hurvitz, S. A., Kalinsky, K., Bardia, A., Henry, S., Mayer, I., Zhu, Y., Phan, S., & Cortés, J. (2022). Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 195(2), 127–139. https://doi.org/10.1007/s10549-022-06602-7

Yap, T. A., Moore, K. N., Patel, M., Henick, B. S., Do, D., Iheanacho, A., Zhang, H., Roche, M., Newberry, K., Hsieh, A., & Juric, D. (2022). 491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors. Annals of Oncology, 33, S765. https://doi.org/10.1016/j.annonc.2022.07.619

Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech-Maranda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C., Lewis, D., Gerson, J. N., … Jurczak, W. (2022). S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 48–49. https://doi.org/10.1097/01.hs9.0000843480.04890.cc

Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Mukherjee, S. D., Mackey, J. R., Abramson, V. G., Oja, C., Wesolowski, R., Thompson, A. M., … Parulekar, W. R. (2022). Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer. JAMA, 327(20), 1963. https://doi.org/10.1001/jama.2022.6147

Diamond, J. R., Boni, V., Lim, E., Nowakowski, G., Cordoba, R., Morillo, D., Valencia, R., Genvresse, I., Merz, C., Boix, O., Frigault, M. M., Greer, J. M., Hamdy, A. M., Huang, X., Izumi, R., Wong, H., & Moreno, V. (2022). First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clinical Cancer Research, 28(7), 1285–1293. https://doi.org/10.1158/1078-0432.ccr-21-3617

Gregory, G. P., Kumar, S., Wang, D., Mahadevan, D., Walker, P., Wagner-Johnston, N., Escobar, C., Bannerji, R., Bhutani, D., Chang, J., Hernandez-Ilizaliturri, F. J., Klein, A., Pagel, J. M., Rybka, W., Yee, A. J., Mohrbacher, A., Huang, M., Farooqui, M., Marinello, P., & Quach, H. (2022). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances, 6(4), 1232–1242. https://doi.org/10.1182/bloodadvances.2021005872

Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O’Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., … Woyach, J. A. (2021). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past Is Prologue” (Shakespeare). Clinical Cancer Research, 28(4), 603–608. https://doi.org/10.1158/1078-0432.ccr-21-1237

Thompson, M. C., Roeker, L. E., Coombs, C. C., Jensen, J. L., Kamdar, M., Skarbnik, A., Pagel, J. M., Bailey, N., Pu, J. J., Jacobs, R., Hill, B. T., Brander, D. M., Shadman, M., Ujjani, C. S., Battiato, K. E., Komari, C. J., Sacchi De Camargo Correia, G., Aronson, J. H., Rhodes, J. M., … Mato, A. R. (2021). Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton’s Tyrosine Kinase Inhibitor and Venetoclax. Blood, 138(Supplement 1), 2628–2628. https://doi.org/10.1182/blood-2021-150751

Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech-Marańda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C. S., Lewis, D. J., Gerson, J. N., … Jurczak, W. (2021). Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. Blood, 138(Supplement 1), 391–391. https://doi.org/10.1182/blood-2021-147599

Mckean, M. A., Lakhani, N. J., Arkenau, H.-T., Symeonides, S., Evans, T. R. J., Lim, E. A., Fontana, E., Bupathi, M., Mclaren, A., Chandana, S. R., Ding, T.-E., Rotolo, J., Capiaux, G., Michel, R., Kaesshaefer, S., Bexon, A., & Falchook, G. S. (2021). 525P Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors. Annals of Oncology, 32, S592. https://doi.org/10.1016/j.annonc.2021.08.1047

Abramson, V., Linden, H. M., Crew, K., Mortimer, J., Alidzanovic, J., Nangia, J., Layman, R., Vranjes, Z. J., Andric, Z., Milovic-Kovacevic, M., Trifunovic, J., Karchmit, Y., Suarez, J., Suster, M., Ptaszynski, M., & Chalasani, P. (2021). 565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer. Annals of Oncology, 32, S619. https://doi.org/10.1016/j.annonc.2021.08.1087

Loibl, S., Loirat, D., Tolaney, S. M., Punie, K., Oliveira, M., Rugo, H. S., Bardia, A., Hurvitz, S. A., Brufsky, A., Kalinsky, K., Cortés, J., O’Shaughnessy, J., Dieras, V. C., Carey, L. A., Gianni, L., Gharaibeh, M., Moore, L., Shi, L., & Piccart, M. (2021). 257P Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Annals of Oncology, 32, S472–S473. https://doi.org/10.1016/j.annonc.2021.08.540